Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Comprehensive characterization of a Canadian cohort of von Hippel-Lindau disease patients.

Salama Y, Albanyan S, Szybowska M, Bullivant G, Gallinger B, Giles RH, Asa S, Badduke C, Chiorean A, Druker H, Ezzat S, Hannah-Shmouni F, Hernandez KG, Inglese C, Jani P, Kaur Y, Krema H, Krimus L, Laperriere N, Lichner Z, Mete O, Sit M, Zadeh G, Jewett MAS, Malkin D, Stockley T, Wasserman JD, Xu W, Schachter NF, Kim RH.

Clin Genet. 2019 Nov;96(5):461-467. doi: 10.1111/cge.13613. Epub 2019 Aug 6.

PMID:
31368132
2.

NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program.

Maani N, Westergard S, Yang J, Scaranelo AM, Telesca S, Thain E, Schachter NF, McCuaig JM, Kim RH.

Cancers (Basel). 2019 May 22;11(5). pii: E707. doi: 10.3390/cancers11050707.

3.

shRNA kinome screen identifies TBK1 as a therapeutic target for HER2+ breast cancer.

Deng T, Liu JC, Chung PE, Uehling D, Aman A, Joseph B, Ketela T, Jiang Z, Schachter NF, Rottapel R, Egan SE, Al-Awar R, Moffat J, Zacksenhaus E.

Cancer Res. 2014 Apr 1;74(7):2119-30. doi: 10.1158/0008-5472.CAN-13-2138. Epub 2014 Jan 31.

4.

Elevated PI3K signaling drives multiple breast cancer subtypes.

Adams JR, Schachter NF, Liu JC, Zacksenhaus E, Egan SE.

Oncotarget. 2011 Jun;2(6):435-47. Review.

Supplemental Content

Loading ...
Support Center